Summary
41.03 -0.08(-0.18%)06/28/2024
Qiagen NV (QGEN)
Qiagen NV (QGEN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.19 | -2.02 | -4.55 | -4.57 | -5.84 | -7.91 | 1.17 | 2,081.71 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 41.03 | |
| Open | 41.13 | |
| High | 41.57 | |
| Low | 40.72 | |
| Volume | 850,756 | |
| Change | -0.08 | |
| Change % | -0.19 | |
| Avg Volume (20 Days) | 923,009 | |
| Volume/Avg Volume (20 Days) Ratio | 0.92 | |
| 52 Week Range | 34.74 - 47.70 | |
| Price vs 52 Week High | -13.99% | |
| Price vs 52 Week Low | 18.09% | |
| Range | -0.26 | |
| Gap Up/Down | -0.38 | |
Fundamentals | ||
| Market Capitalization (Mln) | 9,116 | |
| EBIDTA | 636,876,032 | |
| PE Ratio | 28.6908 | |
| PEG Ratio | 1.2466 | |
| WallStreet Target Price | 50.18 | |
| Book Value | 16.2260 | |
| Earnings Per Share | 1.5200 | |
| EPS Estimate Current Quarter | 0.4400 | |
| EPS Estimate Next Quarter | 0.5200 | |
| EPS Estimate Current Year | 2.1100 | |
| EPS Estimate Next Year | 2.2800 | |
| Diluted EPS (TTM) | 1.5200 | |
| Revenues | ||
| Profit Marging | 0.1738 | |
| Operating Marging (TTM) | 0.2141 | |
| Return on asset (TTM) | 0.0456 | |
| Return on equity (TTM) | 0.0941 | |
| Revenue TTM | 1,938,708,992 | |
| Revenue per share TTM | 8.7330 | |
| Quarterly Revenue Growth (YOY) | -0.0550 | |
| Quarterly Earnings Growth (YOY) | -0.0560 | |
| Gross Profit (TTM) | 1,437,113,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | 0.0294 | |
| Valuations | ||
| Trailing PE | 28.6908 | |
| Forward PE | 18.8324 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.3358 | |
| Revenue Enterprise Value | 4.7669 | |
| EBITDA Enterprise Value | 13.6059 | |
| Shares | ||
| Shares Outstanding | 221,847,008 | |
| Shares Float | 219,834,848 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 0.41 | |
| Institutions (%) | 77.78 | |
06/28 09:25 EST - zacks.com
QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test
QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.
QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test
QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.
06/27 16:05 EST - globenewswire.com
QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children
American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infection American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infection
QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children
American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infection American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infection
06/19 09:10 EST - zacks.com
QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
06/17 08:36 EST - zacks.com
QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
06/17 07:30 EST - globenewswire.com
QIAGEN announces 2028 strategy for solid profitable growth
Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028 // Targeting at least 31% CER adjusted operating income margin in 2028 from portfolio streamlining (including NeuMoDx decision), operational efficiency gains and digitization // Ensuring disciplined capital allocation with high level of R&D and digital investments, focus on value-creating M&A opportunities and plans to return at least $1 billion to shareholders Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028 // Targeting at least 31% CER adjusted operating income margin in 2028 from portfolio streamlining (including NeuMoDx decision), operational efficiency gains and digitization // Ensuring disciplined capital allocation with high level of R&D and digital investments, focus on value-creating M&A opportunities and plans to return at least $1 billion to shareholders
QIAGEN announces 2028 strategy for solid profitable growth
Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028 // Targeting at least 31% CER adjusted operating income margin in 2028 from portfolio streamlining (including NeuMoDx decision), operational efficiency gains and digitization // Ensuring disciplined capital allocation with high level of R&D and digital investments, focus on value-creating M&A opportunities and plans to return at least $1 billion to shareholders Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028 // Targeting at least 31% CER adjusted operating income margin in 2028 from portfolio streamlining (including NeuMoDx decision), operational efficiency gains and digitization // Ensuring disciplined capital allocation with high level of R&D and digital investments, focus on value-creating M&A opportunities and plans to return at least $1 billion to shareholders
06/13 16:05 EST - globenewswire.com
QIAGEN's software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs
Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flagging of co-occurring variants and improved muti-user functionality for faster and more efficient workflows // Genomics are moving towards analyzing large, comprehensive gene panels, creating a need for enhanced scalability Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flagging of co-occurring variants and improved muti-user functionality for faster and more efficient workflows // Genomics are moving towards analyzing large, comprehensive gene panels, creating a need for enhanced scalability
QIAGEN's software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs
Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flagging of co-occurring variants and improved muti-user functionality for faster and more efficient workflows // Genomics are moving towards analyzing large, comprehensive gene panels, creating a need for enhanced scalability Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flagging of co-occurring variants and improved muti-user functionality for faster and more efficient workflows // Genomics are moving towards analyzing large, comprehensive gene panels, creating a need for enhanced scalability
06/12 16:05 EST - globenewswire.com
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through green energy procurement, complemented by 7% decrease in plastic usage // Social: // Leveraging partnerships, QIAGEN broadens diagnostic access worldwide // Commits to goal of at least 40% women in leadership by 2027 // Governance: New Supplier Code of Conduct and Human Rights Committee, upholding high ethical standards across supply chain ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through green energy procurement, complemented by 7% decrease in plastic usage // Social: // Leveraging partnerships, QIAGEN broadens diagnostic access worldwide // Commits to goal of at least 40% women in leadership by 2027 // Governance: New Supplier Code of Conduct and Human Rights Committee, upholding high ethical standards across supply chain
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through green energy procurement, complemented by 7% decrease in plastic usage // Social: // Leveraging partnerships, QIAGEN broadens diagnostic access worldwide // Commits to goal of at least 40% women in leadership by 2027 // Governance: New Supplier Code of Conduct and Human Rights Committee, upholding high ethical standards across supply chain ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through green energy procurement, complemented by 7% decrease in plastic usage // Social: // Leveraging partnerships, QIAGEN broadens diagnostic access worldwide // Commits to goal of at least 40% women in leadership by 2027 // Governance: New Supplier Code of Conduct and Human Rights Committee, upholding high ethical standards across supply chain
06/11 16:05 EST - globenewswire.com
QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance
35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN's comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN's comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17
QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance
35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN's comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN's comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17
06/10 10:05 EST - zacks.com
QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform
QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform
QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
06/06 16:05 EST - globenewswire.com
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period
NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends // Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impact on 2024 sales // Restructuring charge of approximately $400 million – including about $300 million of non-cash charges – planned to be recognized primarily in 2024 NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends // Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impact on 2024 sales // Restructuring charge of approximately $400 million – including about $300 million of non-cash charges – planned to be recognized primarily in 2024
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period
NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends // Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impact on 2024 sales // Restructuring charge of approximately $400 million – including about $300 million of non-cash charges – planned to be recognized primarily in 2024 NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends // Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impact on 2024 sales // Restructuring charge of approximately $400 million – including about $300 million of non-cash charges – planned to be recognized primarily in 2024
06/05 16:05 EST - globenewswire.com
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe
New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers' customization needs, complementing QIAGEN's existing pre-designed assays // GeneGlobe Design and Analysis Hub receives further enhancements, improving user experience and capabilities to design panels collaboratively // Advancements strengthen QIAGEN as a trusted partner for researchers, catering to their diverse needs to further accelerate drug discovery and other applications New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers' customization needs, complementing QIAGEN's existing pre-designed assays // GeneGlobe Design and Analysis Hub receives further enhancements, improving user experience and capabilities to design panels collaboratively // Advancements strengthen QIAGEN as a trusted partner for researchers, catering to their diverse needs to further accelerate drug discovery and other applications
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe
New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers' customization needs, complementing QIAGEN's existing pre-designed assays // GeneGlobe Design and Analysis Hub receives further enhancements, improving user experience and capabilities to design panels collaboratively // Advancements strengthen QIAGEN as a trusted partner for researchers, catering to their diverse needs to further accelerate drug discovery and other applications New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers' customization needs, complementing QIAGEN's existing pre-designed assays // GeneGlobe Design and Analysis Hub receives further enhancements, improving user experience and capabilities to design panels collaboratively // Advancements strengthen QIAGEN as a trusted partner for researchers, catering to their diverse needs to further accelerate drug discovery and other applications
06/05 09:21 EST - zacks.com
QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu
QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.
QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu
QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.
06/03 09:26 EST - zacks.com
QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
06/03 02:00 EST - globenewswire.com
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves
05/31 10:41 EST - zacks.com
QIAGEN (QGEN) Develops Test for Research and CDx Application
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
QIAGEN (QGEN) Develops Test for Research and CDx Application
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
05/30 16:05 EST - globenewswire.com
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN's QIAseq xHYB technology, QIAGEN Digitial Insight solutions, and Myriad's proprietary, FDA-approved MyChoice CDx® biomarkers // QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx // Project builds on recently announced master collaboration agreement between the two companies Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN's QIAseq xHYB technology, QIAGEN Digitial Insight solutions, and Myriad's proprietary, FDA-approved MyChoice CDx® biomarkers // QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx // Project builds on recently announced master collaboration agreement between the two companies
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN's QIAseq xHYB technology, QIAGEN Digitial Insight solutions, and Myriad's proprietary, FDA-approved MyChoice CDx® biomarkers // QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx // Project builds on recently announced master collaboration agreement between the two companies Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN's QIAseq xHYB technology, QIAGEN Digitial Insight solutions, and Myriad's proprietary, FDA-approved MyChoice CDx® biomarkers // QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx // Project builds on recently announced master collaboration agreement between the two companies
05/29 16:05 EST - globenewswire.com
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time
05/29 12:35 EST - zacks.com
Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
05/23 09:17 EST - seekingalpha.com
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
05/16 09:47 EST - zacks.com
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.